Makes precision valves and pumps for inhalers and nasal sprays that are locked into drug approvals by the FDA.
At a glance
- Depends onUpstream position: supplies 4 industries, depends on 0
- ScaleMarket cap is above the global median
Makes precision valves and pumps for inhalers and nasal sprays that are locked into drug approvals by the FDA.
What this company is and how it runs — written from structure, not news.
AptarGroup makes the valves and pumps that meter doses out of inhalers and nasal sprays, and because the FDA treats each specific valve geometry as part of the drug product itself — not just its container — every pharmaceutical customer's regulatory approval is tied to AptarGroup's exact component dimensions. That link means a drug company wanting to switch suppliers cannot simply find a cheaper valve; it must run 18 to 24 months of stability studies to satisfy the FDA before it can sell a single unit with the new part, which makes switching cost more than it saves for almost any product already on the market. The geometry at the center of this lock-in is a precision-ground valve seat whose internal surface tolerances cannot be read from the outside of a finished dispenser, so a competitor cannot reverse-engineer it — they would have to develop their own geometry from scratch and then ask pharmaceutical customers to restart that same 18-to-24-month clock all over again. The one fragile point in the whole chain is that the grinding step producing those seats runs through a single supplier, and if that operation stopped or changed its process, the registered geometry would change with it, triggering the very revalidation cycle that currently keeps customers locked in place.
How does this company make money?
The company charges per unit sold, with the price per unit tied to how large the order is. When a customer needs a pump or valve built to their own specific shape, the company also charges an upfront fee to design and build the mold, and that fee is paid back gradually through a commitment to buy a minimum number of units over several years.
What makes this company hard to replace?
A pharmaceutical customer that wants to move to a different valve supplier must run 18 to 24 months of stability studies and revalidation, because the FDA considers the pump mechanism part of the approved drug product — not a replaceable part. On top of that, the custom molds built for a specific pump geometry belong to the program and cannot be picked up and moved to a competing manufacturer, so even the physical tooling investment keeps customers in place.
What limits this company?
Every different pump or valve design needs its own custom mold, and switching between molds takes 8 to 12 hours of careful recalibration inside a cleanroom. Because each pharmaceutical customer needs its own validated shape, the company can only run as many customer programs at once as it has molds and cleanroom scheduling slots to support — not as many as its raw plastic-pressing capacity would otherwise allow.
What does this company depend on?
The company cannot run without thermoplastic resins that meet USP Class VI biocompatibility standards, injection molding machines capable of operating inside cleanroom conditions, FDA Drug Master File registrations for its dispensing components, ISO 13485 facility certifications, and spring steel components used in the pump mechanisms.
Who depends on this company?
Pharmaceutical companies making metered-dose inhalers rely on these valves being available during the regulatory approval process — if valves became unavailable, drug launches would be delayed. Personal care brands using airless pump dispensers would face expensive product reformulations, because switching to a different dispensing mechanism changes how the product preserves itself and how thick it needs to be.
How does this company scale?
Adding more injection molding lines inside existing cleanroom facilities can grow raw production volume relatively cheaply. What does not scale is the customer side: every new dispensing component a pharmaceutical customer adopts must go through a 12 to 18 month qualification and stability testing process that no amount of capital spending can shorten.
What external forces can significantly affect this company?
The European Single Use Plastics Directive requires that pump components be recyclable, which forces the company to redesign parts that were previously built from mixed materials that cannot be separated for recycling. On the cost side, currency swings affect the price of imported thermoplastic resins, making it harder to predict profit margins across the company's manufacturing sites.
Where is this company structurally vulnerable?
The grinding step that creates the valve seat currently runs through a single supplier. If that supplier lost capacity, changed its process, or shut down, the company could not simply move the work to another grinder — a different machine would produce a measurably different surface, which would count as a component change, trigger full pharmaceutical revalidation for every affected customer, and destroy the regulatory lock-in that makes the valves irreplaceable.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: a high share of the trailing three years' weekly closes were higher than the prior week, the company has reported positive net income in each of the last five annual periods, and the book-value-increase-consistency composite over the trailing 5 years is elevated.
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
OCF is at or above net income for the most recent year; gross profit increased across the last 4 year-over-year transitions; EBIT margin is above the company's historical median while recent sales growth is below baseline (industry-benchmarked composite).
Is this company growing?
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph